Biopolym. Cell. 2015; 31(2):123-130.
Molecular Biomedicine
Novel gene PUS3 c.A212G mutation in Ukrainian family with intellectual disability
1, 2Gulkovskyi R. V., 1Chernushyn S. Y., 1, 2Livshits L. A.
  1. Institute of Molecular Biology and Genetics, NAS of Ukraine
    150, Akademika Zabolotnoho Str., Kyiv, Ukraine, 03680
  2. Educational and Scientific Center "Institute of Biology",
    Taras Shevchenko National University of Kyiv
    64/13, Volodymyrska Str., Kyiv, Ukraine, 01601

Abstract

Aim. To evaluate a possible role of a novel c.A212G substitution in the PUS3 gene at intellectual disability (ID). Methods. The observed group consisted of the ID Ukrainian family members (parents and two affected children) and the control group – of 300 healthy individuals from general population of Ukraine. Sanger sequencing of the PUS3 gene exon 1 was performed for the family members. Polymorphic variants of c.A212G were analyzed using ARMS PCR. The homology models of wild type and p.Y71C mutant catalytic domains of human Pus3 were generated using the crystal structure of the human Pus1 catalytic domain (PDB ID: 4NZ6) as a template. Results. It was shown that the father of the affected siblings was the c.A212G substitution heterozygous carrier whereas the mother was a wild type allele homozygote, and the exom sequencing result was confirmed – the affected children are 212G homozygotes. We supposed de novo mutation in the maternal germ line. A low frequency of 212G allele (0.0017) was shown in the population of Ukraine. Homology modelling of the wild type and p.Y71C mutant catalytic domain of human Pus3 revealed that substitution p.Y71C is located in close proximity to its active site. Conclusions. The absence of hypoproteinemia in our patients, homozygous for the 212C allele allows us to assume that the mutation c.A212G PUS3 is rather neutral and cannot be the major cause of ID. However, considering a low frequency of the 212G allele in the population and close localization of p.Y71C substitution to the active site of hPus3 we cannot exclude that the c.A212G mutation in PUS3 may be a modifier for some pathologies including syndromic ID.
Keywords: PUS3 gene, intellectual disability, mutation, population, pseudouridine

References

[1] Gulkovskyi RV, Chernushyn SY, Kravchenko SA, Bychkova GM, Livshits LA. EPHA1 gene SNPs analysis in population of Ukraine. Biopolym Cell. 2013;29(6):506–10.
[2] Satoh J, Kawana N, Yamamoto Y. Pathway Analysis of ChIP-Seq-Based NRF1 Target Genes Suggests a Logical Hypothesis of their Involvement in the Pathogenesis of Neurodegenerative Diseases. Gene Regul Syst Bio. 2013;7:139-52.
[3] Chen J, Patton JR. Pseudouridine synthase 3 from mouse modifies the anticodon loop of tRNA. Biochemistry. 2000;39(41):12723-30.
[4] Zhao X, Patton JR, Ghosh SK, Fischel-Ghodsian N, Shen L, Spanjaard RA. Pus3p- and Pus1p-dependent pseudouridylation of steroid receptor RNA activator controls a functional switch that regulates nuclear receptor signaling. Mol Endocrinol. 2007;21(3):686-99.
[5] Agris PF. Decoding the genome: a modified view. Nucleic Acids Res. 2004;32(1):223-38.
[6] Tomita K, Ueda T, Watanabe K. The presence of pseudouridine in the anticodon alters the genetic code: a possible mechanism for assignment of the AAA lysine codon as asparagine in echinoderm mitochondria. Nucleic Acids Res. 1999;27(7):1683-9.
[7] Zerfass K, Beier H. Pseudouridine in the anticodon G psi A of plant cytoplasmic tRNA(Tyr) is required for UAG and UAA suppression in the TMV-specific context. Nucleic Acids Res. 1992;20(22):5911-8.
[8] Perret V, Garcia A, Grosjean H, Ebel JP, Florentz C, Gieg? R. Relaxation of a transfer RNA specificity by removal of modified nucleotides. Nature. 1990;344(6268):787-9.
[9] Bykhovskaya Y, Casas K, Mengesha E, Inbal A, Fischel-Ghodsian N. Missense mutation in pseudouridine synthase 1 (PUS1) causes mitochondrial myopathy and sideroblastic anemia (MLASA). Am J Hum Genet. 2004;74(6):1303-8.
[10] Fernandez-Vizarra E, Berardinelli A, Valente L, Tiranti V, Zeviani M. Nonsense mutation in pseudouridylate synthase 1 (PUS1) in two brothers affected by myopathy, lactic acidosis and sideroblastic anaemia (MLASA). J Med Genet. 2007;44(3):173-80.
[11] Patton JR, Bykhovskaya Y, Mengesha E, Bertolotto C, Fischel-Ghodsian N. Mitochondrial myopathy and sideroblastic anemia (MLASA): missense mutation in the pseudouridine synthase 1 (PUS1) gene is associated with the loss of tRNA pseudouridylation. J Biol Chem. 2005;280(20):19823-8.
[12] Cordell HJ, Clayton DG. Genetic association studies. Lancet. 2005 Sep 24-30;366(9491):1121-31.
[13] Balding DJ. A tutorial on statistical methods for population association studies. Nat Rev Genet. 2006;7(10):781-91.
[14] Lecointe F, Simos G, Sauer A, Hurt EC, Motorin Y, Grosjean H. Characterization of yeast protein Deg1 as pseudouridine synthase (Pus3) catalyzing the formation of psi 38 and psi 39 in tRNA anticodon loop. J Biol Chem. 1998;273(3):1316-23.
[15] Chen J, Patton JR. Mouse pseudouridine synthase 1: gene structure and alternative splicing of pre-mRNA. Biochem J. 2000;352 Pt 2:465-73.
[16] Behm-Ansmant I, Massenet S, Immel F, Patton JR, Motorin Y, Branlant C. A previously unidentified activity of yeast and mouse RNA:pseudouridine synthases 1 (Pus1p) on tRNAs. RNA. 2006;12(8):1583-93.
[17] Zhao X, Patton JR, Davis SL, Florence B, Ames SJ, Spanjaard RA. Regulation of nuclear receptor activity by a pseudouridine synthase through posttranscriptional modification of steroid receptor RNA activator. Mol Cell. 2004;15(4):549-58.
[18] Kammen HO, Marvel CC, Hardy L, Penhoet EE. Purification, structure, and properties of Escherichia coli tRNA pseudouridine synthase I. J Biol Chem. 1988;263(5):2255-63.
[19] Chen J, Patton JR. Cloning and characterization of a mammalian pseudouridine synthase. RNA. 1999;5(3):409-19.
[20] Motorin Y, Keith G, Simon C, Foiret D, Simos G, Hurt E, Grosjean H. The yeast tRNA:pseudouridine synthase Pus1p displays a multisite substrate specificity. RNA. 1998;4(7):856-69.
[21] McCleverty CJ, Hornsby M, Spraggon G, Kreusch A. Crystal structure of human Pus10, a novel pseudouridine synthase. J Mol Biol. 2007;373(5):1243-54.
[22] Foster PG, Huang L, Santi DV, Stroud RM. The structural basis for tRNA recognition and pseudouridine formation by pseudouridine synthase I. Nat Struct Biol. 2000;7(1):23-7.
[23] Sivaraman J, Sauv? V, Larocque R, Stura EA, Schrag JD, Cygler M, Matte A. Structure of the 16S rRNA pseudouridine synthase RsuA bound to uracil and UMP. Nat Struct Biol. 2002;9(5):353-8.
[24] Ericsson UB, Nordlund P, Hallberg BM. X-ray structure of tRNA pseudouridine synthase TruD reveals an inserted domain with a novel fold. FEBS Lett. 2004;565(1-3):59-64.
[25] Mizutani K, Machida Y, Unzai S, Park SY, Tame JR. Crystal structures of the catalytic domains of pseudouridine synthases RluC and RluD from Escherichia coli. Biochemistry. 2004;43(15):4454-63.
[26] Koonin EV. Pseudouridine synthases: four families of enzymes containing a putative uridine-binding motif also conserved in dUTPases and dCTP deaminases. Nucleic Acids Res. 1996;24(12):2411-5.
[27] Czudnochowski N, Wang AL, Finer-Moore J, Stroud RM. In human pseudouridine synthase 1 (hPus1), a C-terminal helical insert blocks tRNA from binding in the same orientation as in the Pus1 bacterial homologue TruA, consistent with their different target selectivities. J Mol Biol. 2013;425(20):3875-87.
[28] Huet T, Miannay FA, Patton JR, Thore S. Steroid receptor RNA activator (SRA) modification by the human pseudouridine synthase 1 (hPus1p): RNA binding, activity, and atomic model. PLoS One. 2014;9(4):e94610.
[29] Simos G, Tekotte H, Grosjean H, Segref A, Sharma K, Tollervey D, Hurt EC. Nuclear pore proteins are involved in the biogenesis of functional tRNA. EMBO J. 1996;15(9):2270-84.
[30] Sibert BS, Fischel-Ghodsian N, Patton JR. Partial activity is seen with many substitutions of highly conserved active site residues in human Pseudouridine synthase 1. RNA. 2008;14(9):1895-906.
[31] Hur S, Stroud RM. How U38, 39, and 40 of many tRNAs become the targets for pseudouridylation by TruA. Mol Cell. 2007;26(2):189-203.
[32] Yu YT, Shu MD, Steitz JA. Modifications of U2 snRNA are required for snRNP assembly and pre-mRNA splicing. EMBO J. 1998;17(19):5783-95.
[33] Winkler ME. Biosynthesis of histidine. In Escherichia coli and Salmonella Cellular and Molecular Biology. 1, 2nd ed. (Neidhardt FC, ed.). Washington DC: ASM Press, 1996; pp. 485–505.
[34] Tsui HC, Arps PJ, Connolly DM, Winkler ME. Absence of hisT-mediated tRNA pseudouridylation results in a uracil requirement that interferes with Escherichia coli K-12 cell division. J Bacteriol. 1991;173(22):7395-400.
[35] Mitchell JR, Wood E, Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature. 1999;402(6761):551-5.